Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists

In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry Jg. 230; S. 114027 - 114037
Hauptverfasser: Papanastasiou, Ioannis P., Georgiadis, Markos-Orestis, Iliopoulos-Tsoutsouvas, Christos, Paronis, Carol A., Brust, Christina A., Tran, Ngan K., Ji, Lipin, Ma, Xiaoyu, Wood, JodiAnne T., Zvonok, Nikolai, Tong, Fei, Bohn, Laura M., Nikas, Spyros P., Makriyannis, Alexandros
Format: Journal Article
Sprache:Englisch
Veröffentlicht: ISSY-LES-MOULINEAUX Elsevier Masson SAS 15.02.2022
Elsevier
Schlagworte:
ISSN:0223-5234, 1768-3254, 1768-3254
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal substitutions. Of the compounds described here, a nabilone analog, AM8936, with the C6′-cyano-substituted side chain, was identified as the most successful analog capable of serving as a potential candidate for further development and a valuable tool for further in vivo studies. AM8936 behaved as a balanced and potent CB1 agonist in functional assays and was a potent and efficacious CB1 agonist in vivo. Our SAR studies are highlighted with the docking of AM8936 on the crystal structure of the hCB1 receptor. [Display omitted] •We explored the C3 side-chain in the hexahydrocannabinol template in terms of chain length and terminal substitution.•The cyclobutyl nabilone analog AM8936 with C6′ cyano-substitution was the most successful.•AM8936 behaved as a balanced and potent CB1 agonist in functional assays.•AM8936 behaved as a potent CB1 agonist in vivo.•Our structure activity relationships are highlighted via docking on the hCB1 crystal structure.
AbstractList In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal substitutions. Of the compounds described here, a nabilone analog, AM8936, with the C6'-cyano-substituted side chain, was identified as the most successful analog capable of serving as a potential candidate for further development and a valuable tool for further in vivo studies. AM8936 behaved as a balanced and potent CB1 agonist in functional assays and was a potent and efficacious CB1 agonist in vivo. Our SAR studies are highlighted with the docking of AM8936 on the crystal structure of the hCB1 receptor.In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal substitutions. Of the compounds described here, a nabilone analog, AM8936, with the C6'-cyano-substituted side chain, was identified as the most successful analog capable of serving as a potential candidate for further development and a valuable tool for further in vivo studies. AM8936 behaved as a balanced and potent CB1 agonist in functional assays and was a potent and efficacious CB1 agonist in vivo. Our SAR studies are highlighted with the docking of AM8936 on the crystal structure of the hCB1 receptor.
In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal substitutions. Of the compounds described here, a nabilone analog, AM8936, with the C6'-cyano-substituted side chain, was identified as the most successful analog capable of serving as a potential candidate for further development and a valuable tool for further in vivo studies. AM8936 behaved as a balanced and potent CB1 agonist in functional assays and was a potent and efficacious CB1 agonist in vivo. Our SAR studies are highlighted with the docking of AM8936 on the crystal structure of the hCB1 receptor.
In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal substitutions. Of the compounds described here, a nabilone analog, AM8936, with the C6′-cyano-substituted side chain, was identified as the most successful analog capable of serving as a potential candidate for further development and a valuable tool for further in vivo studies. AM8936 behaved as a balanced and potent CB1 agonist in functional assays and was a potent and efficacious CB1 agonist in vivo. Our SAR studies are highlighted with the docking of AM8936 on the crystal structure of the hCB1 receptor. [Display omitted] •We explored the C3 side-chain in the hexahydrocannabinol template in terms of chain length and terminal substitution.•The cyclobutyl nabilone analog AM8936 with C6′ cyano-substitution was the most successful.•AM8936 behaved as a balanced and potent CB1 agonist in functional assays.•AM8936 behaved as a potent CB1 agonist in vivo.•Our structure activity relationships are highlighted via docking on the hCB1 crystal structure.
In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of nabilone and AM2389 and explored the C3 side chain with varying chain lengths and terminal substitutions. Of the compounds described here, a nabilone analog, AM8936, with the C6'-cyano-substituted side chain, was identified as the most successful analog capable of serving as a potential candidate for further development and a valuable tool for further in vivo studies. AM8936 behaved as a balanced and potent CB1 agonist in functional assays and was a potent and efficacious CB1 agonist in vivo. Our SAR studies are highlighted with the docking of AM8936 on the crystal structure of the hCB1 receptor. (C) 2021 Published by Elsevier Masson SAS.
ArticleNumber 114027
Author Wood, JodiAnne T.
Tong, Fei
Ma, Xiaoyu
Makriyannis, Alexandros
Georgiadis, Markos-Orestis
Papanastasiou, Ioannis P.
Brust, Christina A.
Bohn, Laura M.
Paronis, Carol A.
Ji, Lipin
Iliopoulos-Tsoutsouvas, Christos
Tran, Ngan K.
Zvonok, Nikolai
Nikas, Spyros P.
Author_xml – sequence: 1
  givenname: Ioannis P.
  orcidid: 0000-0001-6974-2561
  surname: Papanastasiou
  fullname: Papanastasiou, Ioannis P.
  organization: Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157-84, Athens, Greece
– sequence: 2
  givenname: Markos-Orestis
  surname: Georgiadis
  fullname: Georgiadis, Markos-Orestis
  organization: Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157-84, Athens, Greece
– sequence: 3
  givenname: Christos
  orcidid: 0000-0003-3750-431X
  surname: Iliopoulos-Tsoutsouvas
  fullname: Iliopoulos-Tsoutsouvas, Christos
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 4
  givenname: Carol A.
  orcidid: 0000-0002-3203-1966
  surname: Paronis
  fullname: Paronis, Carol A.
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 5
  givenname: Christina A.
  orcidid: 0000-0003-2849-0040
  surname: Brust
  fullname: Brust, Christina A.
  organization: Skaggs Graduate School of Chemical and Biological Science and Department of Molecular Medicine, Scripps Florida, Jupiter, FL, 33458, USA
– sequence: 6
  givenname: Ngan K.
  surname: Tran
  fullname: Tran, Ngan K.
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 7
  givenname: Lipin
  orcidid: 0000-0001-9956-3855
  surname: Ji
  fullname: Ji, Lipin
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 8
  givenname: Xiaoyu
  orcidid: 0000-0002-9612-4774
  surname: Ma
  fullname: Ma, Xiaoyu
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 9
  givenname: JodiAnne T.
  surname: Wood
  fullname: Wood, JodiAnne T.
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 10
  givenname: Nikolai
  orcidid: 0000-0002-1749-7688
  surname: Zvonok
  fullname: Zvonok, Nikolai
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 11
  givenname: Fei
  surname: Tong
  fullname: Tong, Fei
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 12
  givenname: Laura M.
  orcidid: 0000-0002-6474-8179
  surname: Bohn
  fullname: Bohn, Laura M.
  organization: Department of Molecular Medicine, Scripps Florida, Jupiter, FL, USA
– sequence: 13
  givenname: Spyros P.
  surname: Nikas
  fullname: Nikas, Spyros P.
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
– sequence: 14
  givenname: Alexandros
  orcidid: 0000-0003-3272-3687
  surname: Makriyannis
  fullname: Makriyannis, Alexandros
  email: a.makriyannis@northeastern.edu
  organization: Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35051750$$D View this record in MEDLINE/PubMed
BookMark eNqNkcFu1DAQhi1URLcLb4BQjkgoy9iJE4cDUkkLVKrEBc6WY4-LV4m9xE7Rvj2usvTAATjZsr5vPDP_BTnzwSMhLynsKNDm7X6H-wn19x0DRneU1sDaJ2RD20aUFeP1GdkAY1XJWVWfk4sY9wDAG4Bn5LziwGnLYUOubqbDHO7RFPqoxzAs6TgWXg1uzL8Vyqsx3MVCxeIQEvpU9B9oMaPGQwpzoe6CdzHF5-SpVWPEF6dzS759vP7afy5vv3y66S9vS12DSCWKoVZa15ZXLTdda4VmFqhAYageBLOobFNRQxuO2mjs8utQ0Q4bNlgQptqS12vd3PKPBWOSk4sax1F5DEuUrGGMiYbnkbfk1QldhgmNPMxuUvNR_p48A29W4CcOwUbt0Gt8xPKqBO1a6ES-Ac20-H-6d0klF3wfFp-yWq-qnkOMM9pHjYJ8SFLu5ZqkfEhSrklm7d0fmj6VTbNy47_k96uMOY17h7M8tWxcDi9JE9zfC_wC8Dq5Ww
CitedBy_id crossref_primary_10_1093_jat_bkae094
crossref_primary_10_1021_acs_jmedchem_5c00047
crossref_primary_10_1021_acs_jmedchem_5c02030
crossref_primary_10_3389_fpsyt_2024_1322434
crossref_primary_10_1016_j_ejphar_2023_176168
Cites_doi 10.1038/nrd.2018.115
10.1016/j.tet.2007.06.006
10.1021/jm501165d
10.1016/j.jagp.2019.05.002
10.1038/nature23272
10.1002/ana.25864
10.1007/s00213-015-3907-0
10.1021/jm050540c
10.1124/jpet.106.104109
10.1021/acs.jctc.5b00864
10.1111/ajad.12622
10.1021/acs.jmedchem.8b00611
10.1124/jpet.119.261818
10.1517/17460441.2012.714363
10.1002/med.21634
10.1021/acs.jmedchem.0c02053
10.1016/j.cell.2020.01.008
10.1021/jm070121a
10.1016/j.bmc.2018.08.003
10.1007/s10822-013-9644-8
10.1016/S0026-895X(25)10492-6
10.1021/jm301205j
10.1016/j.cell.2018.11.040
10.1021/jm100641g
10.1021/acs.jmedchem.6b00717
10.1016/j.cell.2016.10.004
10.1097/FBP.0b013e32835a7c4d
10.1038/s41582-019-0284-z
10.1016/j.jns.2020.116717
10.1016/j.pharmthera.2020.107477
10.1007/s00213-011-2491-1
10.4137/PMC.S32171
ContentType Journal Article
Copyright 2021
Copyright © 2021. Published by Elsevier Masson SAS.
Copyright_xml – notice: 2021
– notice: Copyright © 2021. Published by Elsevier Masson SAS.
DBID AAYXX
CITATION
17B
1KM
AHQBO
BLEPL
DTL
EGQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ejmech.2021.114027
DatabaseName CrossRef
Web of Knowledge
Index Chemicus
Web of Science - Science Citation Index Expanded - 2022
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Web of Science
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KM
  name: Index Chemicus
  url: https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1768-3254
ExternalDocumentID 35051750
000819709800001
10_1016_j_ejmech_2021_114027
S022352342100876X
Genre Journal Article
GrantInformation_xml – fundername: National Institute on Drug Abuse; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)
  grantid: DA009158; DA041435
GroupedDBID ---
--K
--M
.~1
0R~
1RT
1~.
1~5
4.4
457
4G.
5GY
5VS
7-5
71M
8P~
9JM
9JN
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARLI
AATCM
AAXUO
ABFRF
ABGSF
ABJNI
ABMAC
ABOCM
ABUDA
ABYKQ
ABZDS
ACDAQ
ACGFO
ACIUM
ACRLP
ADBBV
ADECG
ADEZE
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AFZHZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJSZI
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
CS3
DOVZS
DU5
EBS
EFJIC
EFLBG
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FLBIZ
FNPLU
FYGXN
G-Q
GBLVA
J1W
KOM
M2Y
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SCC
SDF
SDG
SES
SPC
SPCBC
SSK
SSP
SSU
SSZ
T5K
~G-
1B1
29G
53G
9DU
AAQXK
AATTM
AAXKI
AAYWO
AAYXX
ABFNM
ABWVN
ABXDB
ACLOT
ACNNM
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGQPQ
AGRDE
AHHHB
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
ASPBG
AVWKF
AZFZN
CITATION
EFKBS
EJD
FEDTE
FGOYB
G-2
HMS
HMT
HVGLF
HZ~
IHE
R2-
SCB
SEW
SOC
SPT
WUQ
~HD
17B
1KM
BLEPL
DTL
GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED
GROUPED_WOS_WEB_OF_SCIENCE
BNPGV
CGR
CUY
CVF
ECM
EIF
NPM
SSH
7X8
ID FETCH-LOGICAL-c408t-e8b4acc4f5375d97f8c2f018e8d1cb82feaf631d165ecdce91cbb319e62bf08d3
ISICitedReferencesCount 6
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000819709800001
ISSN 0223-5234
1768-3254
IngestDate Sun Sep 28 11:56:27 EDT 2025
Thu Apr 03 07:08:13 EDT 2025
Mon Oct 27 23:26:35 EDT 2025
Fri Dec 05 22:59:20 EST 2025
Sat Nov 29 07:19:43 EST 2025
Tue Nov 18 22:29:23 EST 2025
Fri Feb 23 02:41:03 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords SAR studies
Cannabinoids
Nabilone analogs
CB1 receptor
AM2389
SIDE-CHAIN
LIGAND
Language English
License Copyright © 2021. Published by Elsevier Masson SAS.
LinkModel OpenURL
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-c408t-e8b4acc4f5375d97f8c2f018e8d1cb82feaf631d165ecdce91cbb319e62bf08d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-9956-3855
0000-0003-2849-0040
0000-0002-9612-4774
0000-0003-3750-431X
0000-0002-3203-1966
0000-0002-6474-8179
0000-0001-6974-2561
0000-0003-3272-3687
0000-0002-1749-7688
0000-0003-2880-8135
0000-0002-9804-9675
OpenAccessLink https://doi.org/10.7270/q2j96bfx
PMID 35051750
PQID 2622286552
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_2622286552
crossref_primary_10_1016_j_ejmech_2021_114027
pubmed_primary_35051750
webofscience_primary_000819709800001
webofscience_primary_000819709800001CitationCount
crossref_citationtrail_10_1016_j_ejmech_2021_114027
elsevier_sciencedirect_doi_10_1016_j_ejmech_2021_114027
PublicationCentury 2000
PublicationDate 2022-02-15
PublicationDateYYYYMMDD 2022-02-15
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-15
  day: 15
PublicationDecade 2020
PublicationPlace ISSY-LES-MOULINEAUX
PublicationPlace_xml – name: ISSY-LES-MOULINEAUX
– name: France
PublicationTitle European journal of medicinal chemistry
PublicationTitleAbbrev EUR J MED CHEM
PublicationTitleAlternate Eur J Med Chem
PublicationYear 2022
Publisher Elsevier Masson SAS
Elsevier
Publisher_xml – name: Elsevier Masson SAS
– name: Elsevier
References Nikas, Sharma, Paronis, Kulkarni, Thakur, Hurst, Wood, Gifford, Rajarshi, Liu, Raghav, Guo, Jarbe, Reggio, Bergman, Makriyannis (bib29) 2015; 58
Martin, Wiley, Beletskaya, Sim-Selley, Smith, Dewey, Cottney, Adams, Baker, Hill, Saha, Zerkowski, Mahadevan, Razdan (bib24) 2006; 318
Kourounakis, Xanthopoulos, Tzara (bib20) 2020; 40
Peball, Krismer, Knaus, Djamshidian, Werkmann, Carbone, Ellmerer, Heim, Marini, Valent, Goebel, Ulmer, Stockner, Wenning, Stolz, Krejcy, Poewe, Seppi (bib7) 2020; 88
Krishna Kumar, Shalev-Benami, Robertson, Hu, Banister, Hollingsworth, Latorraca, Kato, Hilger, Maeda, Weis, Farrens, Dror, Malhotra, Kobilka, Skiniotis (bib11) 2019; 176
Hill, Palastro, Gruber, Fitzmaurice, Greenfield, Lukas, Weiss (bib8) 2017; 26
Hua, Li, Wu, Iliopoulos-Tsoutsouvas, Wang, Wu, Shen, Johnston, Nikas, Song, Song, Yuan, Sun, Wu, Jiang, Grim, Benchama, Stahl, Zvonok, Zhao, Bohn, Makriyannis, Liu (bib12) 2020; 180
Paronis, Nikas, Shukla, Makriyannis (bib17) 2012; 23
Jiang, Iliopoulos-Tsoutsouvas, Tong, Brust, Keenan, Raghav, Hua, Wu, Ho, Wu, Grim, Zvonok, Thakur, Liu, Sharkey, Bohn, Nikas, Makriyannis (bib19) 2021; 64
Arnott, Planey (bib25) 2012; 7
Cristino, Bisogno, Di Marzo (bib3) 2020; 16
Kangas, Zakarian, Vemuri, Alapafuja, Jiang, Nikas, Makriyannis, Bergman (bib15) 2020; 372
Malamas, Raghav, Ma, Honrao, Wood, Benchama, Zhou, Mallipeddi, Makriyannis (bib28) 2018; 26
Felder, Joyce, Briley, Mansouri, Mackie, Blond, Lai, Ma, Mitchell (bib26) 1995; 48
Harder, Damm, Maple, Wu, Reboul, Xiang, Wang, Lupyan, Dahlgren, Knight, Kaus, Cerutti, Krilov, Jorgensen, Abel, Friesner (bib34) 2016; 12
Cinar, Iyer, Kunos (bib2) 2020
Sherman, Day, Jacobson, Friesner, Farid (bib33) 2006; 49
Hua, Vemuri, Nikas, Laprairie, Wu, Qu, Pu, Korde, Jiang, Ho, Han, Ding, Li, Liu, Hanson, Zhao, Bohn, Makriyannis, Stevens, Liu (bib10) 2017; 547
Alapafuja, Nikas, Bharathan, Shukla, Nasr, Bowman, Zvonok, Li, Shi, Engen, Makriyannis (bib21) 2012; 55
Tai, Nikas, Shukla, Vemuri, Makriyannis, Jarbe (bib16) 2015; 232
Nikas, Thakur, Parrish, Alapafuja, Huestis, Makriyannis (bib22) 2007; 63
Di Marzo (bib5) 2018; 17
Levinsohn, Hill (bib4) 2020; 411
Sastry, Adzhigirey, Day, Annabhimoju, Sherman (bib32) 2013; 27
Iliopoulos-Tsoutsouvas, Georgiadis, Ji, Nikas, Makriyannis (bib1) 2020
Järbe, Tai, LeMay, Nikas, Shukla, Zvonok, Makriyannis (bib18) 2012; 220
Liu, Ji, Eno, Kudalkar, Li, Schimpgen, Benchama, Morales, Xu, Hurst, Wu, Mohammad, Wood, Zvonok, Papahatjis, Zhou, Honrao, Mackie, Reggio, Hohmann, Marnett, Makriyannis, Nikas (bib31) 2018; 61
Herrmann, Ruthirakuhan, Gallagher, Verhoeff, Kiss, Black, Lanctot (bib6) 2019; 27
Kulkarni, Nikas, Sharma, Jiang, Paronis, Leonard, Zhang, Honrao, Mallipeddi, Raghav, Benchama, Jarbe, Bergman, Makriyannis (bib30) 2016; 59
Nikas, Alapafuja, Papanastasiou, Paronis, Shukla, Papahatjis, Bowman, Halikhedkar, Han, Makriyannis (bib13) 2010; 53
Ballesteros, Weinstein (bib27) 1995; vol. 25
Papahatjis, Nahmias, Nikas, Andreou, Alapafuja, Tsotinis, Guo, Fan, Makriyannis (bib14) 2007; 50
Hua, Vemuri, Pu, Qu, Han, Wu, Zhao, Shui, Li, Korde, Laprairie, Stahl, Ho, Zvonok, Zhou, Kufareva, Wu, Zhao, Hanson, Bohn, Makriyannis, Stevens, Liu (bib9) 2016; 167
Bow, Rimoldi (bib23) 2016; 8
Nikas (10.1016/j.ejmech.2021.114027_bib22) 2007; 63
Arnott (10.1016/j.ejmech.2021.114027_bib25) 2012; 7
Felder (10.1016/j.ejmech.2021.114027_bib26) 1995; 48
Alapafuja (10.1016/j.ejmech.2021.114027_bib21) 2012; 55
Cristino (10.1016/j.ejmech.2021.114027_bib3) 2020; 16
Sastry (10.1016/j.ejmech.2021.114027_bib32) 2013; 27
Kangas (10.1016/j.ejmech.2021.114027_bib15) 2020; 372
Hua (10.1016/j.ejmech.2021.114027_bib9) 2016; 167
Harder (10.1016/j.ejmech.2021.114027_bib34) 2016; 12
Järbe (10.1016/j.ejmech.2021.114027_bib18) 2012; 220
Martin (10.1016/j.ejmech.2021.114027_bib24) 2006; 318
Paronis (10.1016/j.ejmech.2021.114027_bib17) 2012; 23
Jiang (10.1016/j.ejmech.2021.114027_bib19) 2021; 64
Iliopoulos-Tsoutsouvas (10.1016/j.ejmech.2021.114027_bib1) 2020
Tai (10.1016/j.ejmech.2021.114027_bib16) 2015; 232
Hua (10.1016/j.ejmech.2021.114027_bib10) 2017; 547
Ballesteros (10.1016/j.ejmech.2021.114027_bib27) 1995; vol. 25
Malamas (10.1016/j.ejmech.2021.114027_bib28) 2018; 26
Krishna Kumar (10.1016/j.ejmech.2021.114027_bib11) 2019; 176
Liu (10.1016/j.ejmech.2021.114027_bib31) 2018; 61
Di Marzo (10.1016/j.ejmech.2021.114027_bib5) 2018; 17
Nikas (10.1016/j.ejmech.2021.114027_bib13) 2010; 53
Peball (10.1016/j.ejmech.2021.114027_bib7) 2020; 88
Kulkarni (10.1016/j.ejmech.2021.114027_bib30) 2016; 59
Hua (10.1016/j.ejmech.2021.114027_bib12) 2020; 180
Kourounakis (10.1016/j.ejmech.2021.114027_bib20) 2020; 40
Hill (10.1016/j.ejmech.2021.114027_bib8) 2017; 26
Bow (10.1016/j.ejmech.2021.114027_bib23) 2016; 8
Cinar (10.1016/j.ejmech.2021.114027_bib2) 2020
Nikas (10.1016/j.ejmech.2021.114027_bib29) 2015; 58
Levinsohn (10.1016/j.ejmech.2021.114027_bib4) 2020; 411
Herrmann (10.1016/j.ejmech.2021.114027_bib6) 2019; 27
Sherman (10.1016/j.ejmech.2021.114027_bib33) 2006; 49
Papahatjis (10.1016/j.ejmech.2021.114027_bib14) 2007; 50
Nikas, SP (WOS:000252083800007) 2007; 63
Bow, EW (WOS:000383809500001) 2016; 8
Ballesteros, J.A. (000819709800001.27) 1995; 25
Kulkarni, S (WOS:000380730600022) 2016; 59
Jiang, S (WOS:000639043300020) 2021; 64
Hua, T (WOS:000386344100021) 2016; 167
Sastry, GM (WOS:000318411400002) 2013; 27
Cinar, R (WOS:000522634400012) 2020; 208
Alapafuja, SO (WOS:000311461500055) 2012; 55
Hua, T (WOS:000406358300039) 2017; 547
Arnott, JA (WOS:000309460800001) 2012; 7
Kourounakis, AP (WOS:000485789400001) 2020; 40
Kangas, BD (WOS:000507945200012) 2020; 372
Malamas, MS (WOS:000446669400001) 2018; 26
Nikas, SP (WOS:000348492100012) 2015; 58
Cristino, L (WOS:000505736100007) 2020; 16
Nikas, SP (WOS:000282544800017) 2010; 53
Tai, S (WOS:000358059700010) 2015; 232
Herrmann, N (WOS:000488523100001) 2019; 27
Martin, BR (WOS:000239878900035) 2006; 318
Iliopoulos-Tsoutsouvas, C. (000819709800001.1) 2020
Peball, M (WOS:000564540900001) 2020; 88
Sherman, W (WOS:000234836200015) 2006; 49
Kumar, KK (WOS:000456526100007) 2019; 176
Paronis, CA (WOS:000310921700009) 2012; 23
Järbe, TUC (WOS:000300781200016) 2012; 220
Hill, KP (WOS:000416114000005) 2017; 26
FELDER, CC (WOS:A1995RX63500009) 1995; 48
Levinsohn, EA (WOS:000525420400030) 2020; 411
Harder, E (WOS:000368322500026) 2016; 12
Di Marzo, V (WOS:000443169700010) 2018; 17
Papahatjis, DP (WOS:000248758600010) 2007; 50
Liu, YP (WOS:000447470700009) 2018; 61
Hua, T (WOS:000514846600005) 2020; 180
References_xml – volume: 55
  start-page: 10074
  year: 2012
  end-page: 10089
  ident: bib21
  article-title: Sulfonyl fluoride inhibitors of fatty acid amide hydrolase
  publication-title: J. Med. Chem.
– volume: 16
  start-page: 9
  year: 2020
  end-page: 29
  ident: bib3
  article-title: Cannabinoids and the expanded endocannabinoid system in neurological disorders
  publication-title: Nat. Rev. Neurol.
– start-page: 48
  year: 2020
  end-page: 88
  ident: bib1
  article-title: Natural compounds and synthetic drugs to target type-1 cannabinoid (CB1) receptor
  publication-title: New Tools to Interrogate Endocannabinoid Signalling
– volume: 23
  start-page: 802
  year: 2012
  end-page: 805
  ident: bib17
  article-title: Δ9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice
  publication-title: Behav. Pharmacol.
– volume: 220
  start-page: 417
  year: 2012
  end-page: 426
  ident: bib18
  article-title: AM2389, a high-affinity, in vivo potent CB 1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice
  publication-title: Psychopharmacology
– volume: 61
  start-page: 8639
  year: 2018
  end-page: 8657
  ident: bib31
  article-title: (R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): a novel chiral potent endocannabinoid ligand with stability to metabolizing enzymes
  publication-title: J. Med. Chem.
– start-page: 107477
  year: 2020
  ident: bib2
  article-title: The therapeutic potential of second and third generation CB1R antagonists
  publication-title: Pharmacol. Ther.
– volume: 53
  start-page: 6996
  year: 2010
  end-page: 7010
  ident: bib13
  article-title: Novel 1',1'-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist
  publication-title: J. Med. Chem.
– volume: 58
  start-page: 665
  year: 2015
  end-page: 681
  ident: bib29
  article-title: Probing the carboxyester side chain in controlled deactivation (-)-delta(8)-tetrahydrocannabinols
  publication-title: J. Med. Chem.
– volume: 27
  start-page: 1161
  year: 2019
  end-page: 1173
  ident: bib6
  article-title: Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease
  publication-title: Am. J. Geriatr. Psychiatr.
– volume: 63
  start-page: 8112
  year: 2007
  end-page: 8123
  ident: bib22
  article-title: A concise methodology for the synthesis of (−)-Δ9-tetrahydrocannabinol and (−)-Δ9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs
  publication-title: Tetrahedron
– volume: 547
  start-page: 468
  year: 2017
  end-page: 471
  ident: bib10
  article-title: Crystal structures of agonist-bound human cannabinoid receptor CB1
  publication-title: Nature
– volume: 176
  start-page: 448
  year: 2019
  end-page: 458
  ident: bib11
  article-title: Structure of a signaling cannabinoid receptor 1-G protein complex
  publication-title: Cell
– volume: 8
  start-page: 17
  year: 2016
  end-page: 39
  ident: bib23
  article-title: The structure–function relationships of classical cannabinoids: CB1/CB2 modulation
  publication-title: Perspect. Med. Chem.
– volume: 59
  start-page: 6903
  year: 2016
  end-page: 6919
  ident: bib30
  article-title: Novel C-Ring-hydroxy-substituted controlled deactivation cannabinergic analogues
  publication-title: J. Med. Chem.
– volume: 180
  start-page: 655
  year: 2020
  end-page: 665
  ident: bib12
  article-title: Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures
  publication-title: Cell
– volume: 64
  start-page: 3870
  year: 2021
  end-page: 3884
  ident: bib19
  article-title: Novel functionalized cannabinoid receptor probes: development of exceptionally potent agonists
  publication-title: J. Med. Chem.
– volume: vol. 25
  start-page: 366
  year: 1995
  end-page: 428
  ident: bib27
  article-title: Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors
  publication-title: Methods Neurosci
– volume: 17
  start-page: 623
  year: 2018
  end-page: 639
  ident: bib5
  article-title: New approaches and challenges to targeting the endocannabinoid system
  publication-title: Nat. Rev. Drug Discov.
– volume: 50
  start-page: 4048
  year: 2007
  end-page: 4060
  ident: bib14
  article-title: C1 ‘-cycloalkyl side chain pharmacophore in tetrahydrocannabinols
  publication-title: J. Med. Chem.
– volume: 372
  start-page: 119
  year: 2020
  end-page: 127
  ident: bib15
  article-title: Cannabinoid antagonist drug discrimination in nonhuman primates
  publication-title: J. Pharmacol. Exp. Therapeut.
– volume: 318
  start-page: 1230
  year: 2006
  end-page: 1239
  ident: bib24
  article-title: Pharmacological characterization of novel water-soluble cannabinoids
  publication-title: J. Pharmacol. Exp. Therapeut.
– volume: 411
  start-page: 116717
  year: 2020
  ident: bib4
  article-title: Clinical uses of cannabis and cannabinoids in the United States
  publication-title: J. Neurol. Sci.
– volume: 232
  start-page: 2751
  year: 2015
  end-page: 2761
  ident: bib16
  article-title: Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist
  publication-title: Psychopharmacology (Berl)
– volume: 49
  start-page: 534
  year: 2006
  end-page: 553
  ident: bib33
  article-title: Novel procedure for modeling ligand/receptor induced fit effects
  publication-title: J. Med. Chem.
– volume: 27
  start-page: 221
  year: 2013
  end-page: 234
  ident: bib32
  article-title: Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
  publication-title: J. Comput. Aided Mol. Des.
– volume: 167
  start-page: 750
  year: 2016
  end-page: 762
  ident: bib9
  article-title: Crystal structure of the human cannabinoid receptor CB1
  publication-title: Cell
– volume: 7
  start-page: 863
  year: 2012
  end-page: 875
  ident: bib25
  article-title: The influence of lipophilicity in drug discovery and design
  publication-title: Expet Opin. Drug Discov.
– volume: 48
  start-page: 443
  year: 1995
  end-page: 450
  ident: bib26
  article-title: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
  publication-title: Mol. Pharmacol.
– volume: 12
  start-page: 281
  year: 2016
  end-page: 296
  ident: bib34
  article-title: OPLS3: a force field providing broad coverage of drug-like small molecules and proteins
  publication-title: J. Chem. Theor. Comput.
– volume: 26
  start-page: 795
  year: 2017
  end-page: 801
  ident: bib8
  article-title: Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study
  publication-title: Am. J. Addict.
– volume: 88
  start-page: 712
  year: 2020
  end-page: 722
  ident: bib7
  article-title: Collaborators of the Parkinson's Disease Working Group, I., Non-motor symptoms in Parkinson's disease are reduced by nabilone
  publication-title: Ann. Neurol.
– volume: 40
  start-page: 709
  year: 2020
  end-page: 752
  ident: bib20
  article-title: Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
  publication-title: Med. Res. Rev.
– volume: 26
  start-page: 4963
  year: 2018
  end-page: 4970
  ident: bib28
  article-title: Oximes short-acting CB1 receptor agonists
  publication-title: Bioorg. Med. Chem.
– volume: 17
  start-page: 623
  issue: 9
  year: 2018
  ident: 10.1016/j.ejmech.2021.114027_bib5
  article-title: New approaches and challenges to targeting the endocannabinoid system
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.115
– volume: 63
  start-page: 8112
  issue: 34
  year: 2007
  ident: 10.1016/j.ejmech.2021.114027_bib22
  article-title: A concise methodology for the synthesis of (−)-Δ9-tetrahydrocannabinol and (−)-Δ9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs
  publication-title: Tetrahedron
  doi: 10.1016/j.tet.2007.06.006
– volume: 58
  start-page: 665
  issue: 2
  year: 2015
  ident: 10.1016/j.ejmech.2021.114027_bib29
  article-title: Probing the carboxyester side chain in controlled deactivation (-)-delta(8)-tetrahydrocannabinols
  publication-title: J. Med. Chem.
  doi: 10.1021/jm501165d
– volume: 27
  start-page: 1161
  issue: 11
  year: 2019
  ident: 10.1016/j.ejmech.2021.114027_bib6
  article-title: Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease
  publication-title: Am. J. Geriatr. Psychiatr.
  doi: 10.1016/j.jagp.2019.05.002
– volume: 547
  start-page: 468
  issue: 7664
  year: 2017
  ident: 10.1016/j.ejmech.2021.114027_bib10
  article-title: Crystal structures of agonist-bound human cannabinoid receptor CB1
  publication-title: Nature
  doi: 10.1038/nature23272
– volume: 88
  start-page: 712
  issue: 4
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib7
  article-title: Collaborators of the Parkinson's Disease Working Group, I., Non-motor symptoms in Parkinson's disease are reduced by nabilone
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.25864
– volume: 232
  start-page: 2751
  issue: 15
  year: 2015
  ident: 10.1016/j.ejmech.2021.114027_bib16
  article-title: Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s00213-015-3907-0
– volume: 49
  start-page: 534
  issue: 2
  year: 2006
  ident: 10.1016/j.ejmech.2021.114027_bib33
  article-title: Novel procedure for modeling ligand/receptor induced fit effects
  publication-title: J. Med. Chem.
  doi: 10.1021/jm050540c
– volume: 318
  start-page: 1230
  issue: 3
  year: 2006
  ident: 10.1016/j.ejmech.2021.114027_bib24
  article-title: Pharmacological characterization of novel water-soluble cannabinoids
  publication-title: J. Pharmacol. Exp. Therapeut.
  doi: 10.1124/jpet.106.104109
– volume: 12
  start-page: 281
  issue: 1
  year: 2016
  ident: 10.1016/j.ejmech.2021.114027_bib34
  article-title: OPLS3: a force field providing broad coverage of drug-like small molecules and proteins
  publication-title: J. Chem. Theor. Comput.
  doi: 10.1021/acs.jctc.5b00864
– volume: 26
  start-page: 795
  issue: 8
  year: 2017
  ident: 10.1016/j.ejmech.2021.114027_bib8
  article-title: Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study
  publication-title: Am. J. Addict.
  doi: 10.1111/ajad.12622
– volume: 61
  start-page: 8639
  issue: 19
  year: 2018
  ident: 10.1016/j.ejmech.2021.114027_bib31
  article-title: (R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): a novel chiral potent endocannabinoid ligand with stability to metabolizing enzymes
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b00611
– start-page: 48
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib1
  article-title: Natural compounds and synthetic drugs to target type-1 cannabinoid (CB1) receptor
– volume: 372
  start-page: 119
  issue: 1
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib15
  article-title: Cannabinoid antagonist drug discrimination in nonhuman primates
  publication-title: J. Pharmacol. Exp. Therapeut.
  doi: 10.1124/jpet.119.261818
– volume: 7
  start-page: 863
  issue: 10
  year: 2012
  ident: 10.1016/j.ejmech.2021.114027_bib25
  article-title: The influence of lipophilicity in drug discovery and design
  publication-title: Expet Opin. Drug Discov.
  doi: 10.1517/17460441.2012.714363
– volume: 40
  start-page: 709
  issue: 2
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib20
  article-title: Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21634
– volume: 64
  start-page: 3870
  issue: 7
  year: 2021
  ident: 10.1016/j.ejmech.2021.114027_bib19
  article-title: Novel functionalized cannabinoid receptor probes: development of exceptionally potent agonists
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c02053
– volume: 180
  start-page: 655
  issue: 4
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib12
  article-title: Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures
  publication-title: Cell
  doi: 10.1016/j.cell.2020.01.008
– volume: 50
  start-page: 4048
  issue: 17
  year: 2007
  ident: 10.1016/j.ejmech.2021.114027_bib14
  article-title: C1 ‘-cycloalkyl side chain pharmacophore in tetrahydrocannabinols
  publication-title: J. Med. Chem.
  doi: 10.1021/jm070121a
– volume: 26
  start-page: 4963
  issue: 18
  year: 2018
  ident: 10.1016/j.ejmech.2021.114027_bib28
  article-title: Oximes short-acting CB1 receptor agonists
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2018.08.003
– volume: 27
  start-page: 221
  issue: 3
  year: 2013
  ident: 10.1016/j.ejmech.2021.114027_bib32
  article-title: Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
  publication-title: J. Comput. Aided Mol. Des.
  doi: 10.1007/s10822-013-9644-8
– volume: 48
  start-page: 443
  issue: 3
  year: 1995
  ident: 10.1016/j.ejmech.2021.114027_bib26
  article-title: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
  publication-title: Mol. Pharmacol.
  doi: 10.1016/S0026-895X(25)10492-6
– volume: 55
  start-page: 10074
  issue: 22
  year: 2012
  ident: 10.1016/j.ejmech.2021.114027_bib21
  article-title: Sulfonyl fluoride inhibitors of fatty acid amide hydrolase
  publication-title: J. Med. Chem.
  doi: 10.1021/jm301205j
– volume: 8
  start-page: 17
  year: 2016
  ident: 10.1016/j.ejmech.2021.114027_bib23
  article-title: The structure–function relationships of classical cannabinoids: CB1/CB2 modulation
  publication-title: Perspect. Med. Chem.
– volume: 176
  start-page: 448
  issue: 3
  year: 2019
  ident: 10.1016/j.ejmech.2021.114027_bib11
  article-title: Structure of a signaling cannabinoid receptor 1-G protein complex
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.040
– volume: vol. 25
  start-page: 366
  year: 1995
  ident: 10.1016/j.ejmech.2021.114027_bib27
  article-title: Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors
– volume: 53
  start-page: 6996
  issue: 19
  year: 2010
  ident: 10.1016/j.ejmech.2021.114027_bib13
  article-title: Novel 1',1'-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist
  publication-title: J. Med. Chem.
  doi: 10.1021/jm100641g
– volume: 59
  start-page: 6903
  issue: 14
  year: 2016
  ident: 10.1016/j.ejmech.2021.114027_bib30
  article-title: Novel C-Ring-hydroxy-substituted controlled deactivation cannabinergic analogues
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.6b00717
– volume: 167
  start-page: 750
  issue: 3
  year: 2016
  ident: 10.1016/j.ejmech.2021.114027_bib9
  article-title: Crystal structure of the human cannabinoid receptor CB1
  publication-title: Cell
  doi: 10.1016/j.cell.2016.10.004
– volume: 23
  start-page: 802
  issue: 8
  year: 2012
  ident: 10.1016/j.ejmech.2021.114027_bib17
  article-title: Δ9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice
  publication-title: Behav. Pharmacol.
  doi: 10.1097/FBP.0b013e32835a7c4d
– volume: 16
  start-page: 9
  issue: 1
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib3
  article-title: Cannabinoids and the expanded endocannabinoid system in neurological disorders
  publication-title: Nat. Rev. Neurol.
  doi: 10.1038/s41582-019-0284-z
– volume: 411
  start-page: 116717
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib4
  article-title: Clinical uses of cannabis and cannabinoids in the United States
  publication-title: J. Neurol. Sci.
  doi: 10.1016/j.jns.2020.116717
– start-page: 107477
  year: 2020
  ident: 10.1016/j.ejmech.2021.114027_bib2
  article-title: The therapeutic potential of second and third generation CB1R antagonists
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2020.107477
– volume: 220
  start-page: 417
  issue: 2
  year: 2012
  ident: 10.1016/j.ejmech.2021.114027_bib18
  article-title: AM2389, a high-affinity, in vivo potent CB 1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-011-2491-1
– volume: 176
  start-page: 448
  year: 2019
  ident: WOS:000456526100007
  article-title: Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
  publication-title: CELL
  doi: 10.1016/j.cell.2018.11.040
– volume: 26
  start-page: 795
  year: 2017
  ident: WOS:000416114000005
  article-title: Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study
  publication-title: AMERICAN JOURNAL ON ADDICTIONS
  doi: 10.1111/ajad.12622
– volume: 59
  start-page: 6903
  year: 2016
  ident: WOS:000380730600022
  article-title: Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.6b00717
– volume: 208
  start-page: ARTN 107477
  year: 2020
  ident: WOS:000522634400012
  article-title: The therapeutic potential of second and third generation CB1R antagonists
  publication-title: PHARMACOLOGY & THERAPEUTICS
  doi: 10.1016/j.pharmthera.2020.107477
– volume: 318
  start-page: 1230
  year: 2006
  ident: WOS:000239878900035
  article-title: Pharmacological characterization of novel water-soluble cannabinoids
  publication-title: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
  doi: 10.1124/jpet.106.104109
– volume: 372
  start-page: 119
  year: 2020
  ident: WOS:000507945200012
  article-title: Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates
  publication-title: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
  doi: 10.1124/jpet.119.261818
– volume: 53
  start-page: 6996
  year: 2010
  ident: WOS:000282544800017
  article-title: Novel 1′,1′-Chain Substituted Hexahydrocannabinols: 9/β-1-Hydroxy-3-(1-hexyl-cyclobut-l-yl)hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm100641g
– volume: 547
  start-page: 468
  year: 2017
  ident: WOS:000406358300039
  article-title: Crystal structures of agonist-bound human cannabinoid receptor CB1
  publication-title: NATURE
  doi: 10.1038/nature23272
– volume: 40
  start-page: 709
  year: 2020
  ident: WOS:000485789400001
  article-title: Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
  publication-title: MEDICINAL RESEARCH REVIEWS
  doi: 10.1002/med.21634
– volume: 88
  start-page: 712
  year: 2020
  ident: WOS:000564540900001
  article-title: Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
  publication-title: ANNALS OF NEUROLOGY
  doi: 10.1002/ana.25864
– volume: 49
  start-page: 534
  year: 2006
  ident: WOS:000234836200015
  article-title: Novel procedure for modeling ligand/receptor induced fit effects
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm050540c
– volume: 17
  start-page: 623
  year: 2018
  ident: WOS:000443169700010
  article-title: New approaches and challenges to targeting the endocannabinoid system
  publication-title: NATURE REVIEWS DRUG DISCOVERY
  doi: 10.1038/nrd.2018.115
– volume: 232
  start-page: 2751
  year: 2015
  ident: WOS:000358059700010
  article-title: Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist
  publication-title: PSYCHOPHARMACOLOGY
  doi: 10.1007/s00213-015-3907-0
– volume: 7
  start-page: 863
  year: 2012
  ident: WOS:000309460800001
  article-title: The influence of lipophilicity in drug discovery and design
  publication-title: EXPERT OPINION ON DRUG DISCOVERY
  doi: 10.1517/17460441.2012.714363
– start-page: 48
  year: 2020
  ident: 000819709800001.1
  article-title: Natural compounds and synthetic drugs to target type-1 cannabinoid (CB1) receptor
  publication-title: New Tools to Interrogate Endocannabinoid Signalling
– volume: 12
  start-page: 281
  year: 2016
  ident: WOS:000368322500026
  article-title: OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
  publication-title: JOURNAL OF CHEMICAL THEORY AND COMPUTATION
  doi: 10.1021/acs.jctc.5b00864
– volume: 55
  start-page: 10074
  year: 2012
  ident: WOS:000311461500055
  article-title: Sulfonyl Fluoride Inhibitors of Fatty Acid Amide Hydrolase
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm301205j
– volume: 23
  start-page: 802
  year: 2012
  ident: WOS:000310921700009
  article-title: Δ9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice
  publication-title: BEHAVIOURAL PHARMACOLOGY
  doi: 10.1097/FBP.0b013e32835a7c4d
– volume: 63
  start-page: 8112
  year: 2007
  ident: WOS:000252083800007
  article-title: A concise methodology for the synthesis of (-)-Δ9-tetrahydrocannabinol and (-)-Δ9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs
  publication-title: TETRAHEDRON
  doi: 10.1016/j.tet.2007.06.006
– volume: 8
  year: 2016
  ident: WOS:000383809500001
  article-title: The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation
  publication-title: PERSPECTIVES IN MEDICINAL CHEMISTRY
  doi: 10.4137/PMC.S32171
– volume: 50
  start-page: 4048
  year: 2007
  ident: WOS:000248758600010
  article-title: C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm070121a
– volume: 16
  start-page: 9
  year: 2020
  ident: WOS:000505736100007
  article-title: Cannabinoids and the expanded endocannabinoid system in neurological disorders
  publication-title: NATURE REVIEWS NEUROLOGY
  doi: 10.1038/s41582-019-0284-z
– volume: 25
  start-page: 366
  year: 1995
  ident: 000819709800001.27
  article-title: Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors
  publication-title: Methods Neurosci
– volume: 180
  start-page: 655
  year: 2020
  ident: WOS:000514846600005
  article-title: Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures
  publication-title: CELL
  doi: 10.1016/j.cell.2020.01.008
– volume: 27
  start-page: 1161
  year: 2019
  ident: WOS:000488523100001
  article-title: Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease
  publication-title: AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
  doi: 10.1016/j.jagp.2019.05.002
– volume: 26
  start-page: 4963
  year: 2018
  ident: WOS:000446669400001
  article-title: Oximes short-acting CB1 receptor agonists
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY
  doi: 10.1016/j.bmc.2018.08.003
– volume: 27
  start-page: 221
  year: 2013
  ident: WOS:000318411400002
  article-title: Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
  publication-title: JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
  doi: 10.1007/s10822-013-9644-8
– volume: 220
  start-page: 417
  year: 2012
  ident: WOS:000300781200016
  article-title: AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice
  publication-title: PSYCHOPHARMACOLOGY
  doi: 10.1007/s00213-011-2491-1
– volume: 167
  start-page: 750
  year: 2016
  ident: WOS:000386344100021
  article-title: Crystal Structure of the Human Cannabinoid Receptor CB1
  publication-title: CELL
  doi: 10.1016/j.cell.2016.10.004
– volume: 58
  start-page: 665
  year: 2015
  ident: WOS:000348492100012
  article-title: Probing the Carboxyester Side Chain in Controlled Deactivation (-)-Δ8-Tetrahydrocannabinols
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm501165d
– volume: 64
  start-page: 3870
  year: 2021
  ident: WOS:000639043300020
  article-title: Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.0c02053
– volume: 48
  start-page: 443
  year: 1995
  ident: WOS:A1995RX63500009
  article-title: COMPARISON OF THE PHARMACOLOGY AND SIGNAL-TRANSDUCTION OF THE HUMAN CANNABINOID CB1 AND CB2 RECEPTORS
  publication-title: MOLECULAR PHARMACOLOGY
– volume: 61
  start-page: 8639
  year: 2018
  ident: WOS:000447470700009
  article-title: (R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.8b00611
– volume: 411
  start-page: ARTN 116717
  year: 2020
  ident: WOS:000525420400030
  article-title: Clinical uses of cannabis and cannabinoids in the United States
  publication-title: JOURNAL OF THE NEUROLOGICAL SCIENCES
  doi: 10.1016/j.jns.2020.116717
SSID ssj0005600
Score 2.393932
Snippet In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted...
Source Web of Science
SourceID proquest
pubmed
webofscience
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 114027
SubjectTerms Cannabinoids
CB1 receptor
Chemistry, Medicinal
Dronabinol - analogs & derivatives
Dronabinol - pharmacology
Life Sciences & Biomedicine
Nabilone analogs
Pharmacology & Pharmacy
Receptor, Cannabinoid, CB1 - agonists
SAR studies
Science & Technology
Structure-Activity Relationship
Title Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists
URI https://dx.doi.org/10.1016/j.ejmech.2021.114027
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000819709800001
https://www.ncbi.nlm.nih.gov/pubmed/35051750
https://www.proquest.com/docview/2622286552
Volume 230
WOS 000819709800001
WOSCitedRecordID wos000819709800001
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1768-3254
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005600
  issn: 0223-5234
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6lLYJeEJRXeFSLVPWSOvL7cQyhiCJUcggoN2u9XqNErm3VTtT8Q34WM16vHRqqhgOHWJFf2fj7PDs7O_sNISdM92vHW3PBPdZsgwuNicDWHO4lbsCEIerKcz--epeX_mwWTHq9X2otzCr1ssy_uQmK_wo17AOwcensP8Dd3hR2wHcAHbYAO2x3Al6GCcCP5Gue5tGyWqeDDHV08wynCjBYU2J1mSKvMA9g_MEYgNUTRYXplD9zVNIt74zXN75rMyOP2iKqYFw3FwX2hYHPidm1tQXKsSxSOZgM21wfjMPPWSzlDXC1UF5q37BIyLz18C_SeV7kyxSOTMt8WcFnxTblEMruB1Het2yzVwaj4WYoA0bBWFjF6eJrjTOwYQLBecGhsgw5CGmiYYCkWaaUnlY23JSTO1v9gQxNLIZicSXquSfTQHVkXeoRbLChuKrpYDmoWSalcP8U577VabapjNKp8vTArydK9siB6TkB2NeD0cX57EuXbuTK5VDqH6llnHWu4XbzDslD1Za7PKbtEdFfnafaUZo-IY-bEQ4dSWY-JT2RHZFHY8WTI3I6kXLp6zM67Vb_lWf0lE46IfX1M_JRUZl2VKaKyrShMmUllVSmQGWqqEwVlZ-T75_Op-PPWlP1Q-O27lea8CObcW4njuU5ceAlPjcT3fCFHxs88s1EsMS1jNhwHcFjLgLYG0FHIlwzSnQ_tl6Q_Qya8YpQS0CHFhlBjLqAni0CMExuBN2qznQ7sVifWOrJhryRxMfKLGmoch8XoYQmRGhCCU2faO1VhZSEued8T4EWNshIdzUElt5z5XuFcQgY4VQey0S-LEPTxcit6zhmn7yU4LdtUbzpk5NNNrTHbzG2T4xdThs3zwelMqrXu936DTnsXvO3ZL-6Xop35AFfgTm5PiZ73sw_bt6T348k9IA
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+cyclobutyl+nabilone+analogs+as+potent+CB1+receptor+agonists&rft.jtitle=European+journal+of+medicinal+chemistry&rft.au=Papanastasiou%2C+Ioannis+P.&rft.au=Georgiadis%2C+Markos-Orestis&rft.au=Iliopoulos-Tsoutsouvas%2C+Christos&rft.au=Paronis%2C+Carol+A.&rft.date=2022-02-15&rft.pub=Elsevier&rft.issn=0223-5234&rft.eissn=1768-3254&rft.volume=230&rft_id=info:doi/10.1016%2Fj.ejmech.2021.114027&rft_id=info%3Apmid%2F35051750&rft.externalDBID=n%2Fa&rft.externalDocID=000819709800001
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0223-5234&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0223-5234&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0223-5234&client=summon